{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:29:52Z","timestamp":1790792992537,"version":"4.1.0"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1011247","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000}}],"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006229","name":"Oak Ridge Institute for Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>\n                    The advancements in next-generation sequencing have made it possible to effectively detect somatic mutations, which has led to the development of personalized neoantigen cancer vaccines that are tailored to the unique variants found in a patient\u2019s cancer. These vaccines can provide significant clinical benefit by leveraging the patient\u2019s immune response to eliminate malignant cells. However, determining the optimal vaccine dose for each patient is a challenge due to the heterogeneity of tumors. To address this challenge, we formulate a mathematical dose optimization problem based on a previous mathematical model that encompasses the immune response cascade produced by the vaccine in a patient. We propose an optimization approach to identify the optimal personalized vaccine doses, considering a fixed vaccination schedule, while simultaneously minimizing the overall number of tumor and activated T cells. To validate our approach, we perform\n                    <jats:italic>in silico<\/jats:italic>\n                    experiments on six real-world clinical trial patients with advanced melanoma. We compare the results of applying an optimal vaccine dose to those of a suboptimal dose (the dose used in the clinical trial and its deviations). Our simulations reveal that an optimal vaccine regimen of higher initial doses and lower final doses may lead to a reduction in tumor size for certain patients. Our mathematical dose optimization offers a promising approach to determining an optimal vaccine dose for each patient and improving clinical outcomes.\n                  <\/jats:p>","DOI":"10.1371\/journal.pcbi.1011247","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T13:45:16Z","timestamp":1709300716000},"page":"e1011247","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-2489","authenticated-orcid":true,"given":"Wencel","family":"Valega-Mackenzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3555-5810","authenticated-orcid":true,"given":"Marisabel","family":"Rodriguez Messan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4987-3753","authenticated-orcid":true,"given":"Osman N.","family":"Yogurtcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujwani","family":"Nukala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuben E.","family":"Sauna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0057-6566","authenticated-orcid":true,"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"pcbi.1011247.ref001","unstructured":"Centers for Disease Control and Prevention, Cancer; Last time accessed November 29, 2022. https:\/\/www.cdc.gov\/cancer\/dcpc\/research\/update-on-cancer-deaths\/index.htm."},{"key":"pcbi.1011247.ref002","unstructured":"World Health Organization; Last time accessed November 29, 2022. https:\/\/www.who.int\/health-topics\/cancer."},{"issue":"7","key":"pcbi.1011247.ref003","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.clinthera.2016.03.026","article-title":"Current challenges in cancer treatment","volume":"38","author":"J Zugazagoitia","year":"2016","journal-title":"Clinical therapeutics"},{"issue":"2","key":"pcbi.1011247.ref004","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized cancer vaccines: clinical landscape, challenges, and opportunities","volume":"29","author":"CS Shemesh","year":"2021","journal-title":"Molecular Therapy"},{"issue":"9","key":"pcbi.1011247.ref005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"I Melero","year":"2014","journal-title":"Nature reviews Clinical oncology"},{"issue":"7378","key":"pcbi.1011247.ref006","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"I Mellman","year":"2011","journal-title":"Nature"},{"key":"pcbi.1011247.ref007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.936129","article-title":"MuSyC dosing of adjuvanted cancer vaccines optimizes antitumor responses","volume":"13","author":"D Taylor","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"pcbi.1011247.ref008","first-page":"1","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"J Liu","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"5","key":"pcbi.1011247.ref009","doi-asserted-by":"crossref","first-page":"e0178479","DOI":"10.1371\/journal.pone.0178479","article-title":"Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model","volume":"12","author":"X Lai","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"pcbi.1011247.ref010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mbs.2007.05.003","article-title":"Optimal control of treatment in a mathematical model of chronic myelogenous leukemia","volume":"210","author":"S Nanda","year":"2007","journal-title":"Mathematical biosciences"},{"issue":"24","key":"pcbi.1011247.ref011","doi-asserted-by":"crossref","first-page":"24TR01","DOI":"10.1088\/1361-6560\/abc3fc","article-title":"Computational modelling of modern cancer immunotherapy","volume":"65","author":"D Valentinuzzi","year":"2020","journal-title":"Physics in Medicine & Biology"},{"issue":"5","key":"pcbi.1011247.ref012","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10928-014-9386-9","article-title":"Modeling cancer-immune responses to therapy","volume":"41","author":"L Depillis","year":"2014","journal-title":"Journal of pharmacokinetics and pharmacodynamics"},{"key":"pcbi.1011247.ref013","doi-asserted-by":"crossref","first-page":"101198","DOI":"10.1016\/j.jocs.2020.101198","article-title":"Cancer modeling: From mechanistic to data-driven approaches, and from fundamental insights to clinical applications","volume":"46","author":"S Bekisz","year":"2020","journal-title":"Journal of Computational Science"},{"issue":"131","key":"pcbi.1011247.ref014","doi-asserted-by":"crossref","first-page":"20170150","DOI":"10.1098\/rsif.2017.0150","article-title":"Addressing current challenges in cancer immunotherapy with mathematical and computational modelling","volume":"14","author":"A Konstorum","year":"2017","journal-title":"Journal of the Royal Society Interface"},{"issue":"14","key":"pcbi.1011247.ref015","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1158\/0008-5472.CAN-06-0241","article-title":"Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model","volume":"66","author":"A Cappuccio","year":"2006","journal-title":"Cancer Research"},{"issue":"12","key":"pcbi.1011247.ref016","doi-asserted-by":"crossref","first-page":"e15482","DOI":"10.1371\/journal.pone.0015482","article-title":"Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models","volume":"5","author":"N Kronik","year":"2010","journal-title":"PloS one"},{"key":"pcbi.1011247.ref017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3389\/fonc.2013.00056","article-title":"A model of dendritic cell therapy for melanoma","volume":"3","author":"L DePillis","year":"2013","journal-title":"Frontiers in oncology"},{"issue":"4","key":"pcbi.1011247.ref018","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41551-020-00662-0","article-title":"A mathematical model for the quantification of a patient\u2019s sensitivity to checkpoint inhibitors and long-term tumour burden","volume":"5","author":"JD Butner","year":"2021","journal-title":"Nature biomedical engineering"},{"key":"pcbi.1011247.ref019","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002850050127","article-title":"Modeling immunotherapy of the tumor\u2013immune interaction","volume":"37","author":"D Kirschner","year":"1998","journal-title":"Journal of mathematical biology"},{"key":"pcbi.1011247.ref020","doi-asserted-by":"crossref","first-page":"108966","DOI":"10.1016\/j.mbs.2023.108966","article-title":"Analysis of tumor-immune functional responses in a mathematical model of neoantigen cancer vaccines","author":"L Han","year":"2023","journal-title":"Mathematical Biosciences"},{"key":"pcbi.1011247.ref021","article-title":"Optimal control for mathematical models of cancer therapies","author":"H Sch\u00e4ttler","year":"2015","journal-title":"An application of geometric methods"},{"issue":"1","key":"pcbi.1011247.ref022","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.mbs.2010.11.007","article-title":"Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function","volume":"229","author":"M Engelhart","year":"2011","journal-title":"Mathematical biosciences"},{"issue":"6","key":"pcbi.1011247.ref023","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1137\/100815190","article-title":"Controlled drug delivery in cancer immunotherapy: Stability, optimization, and Monte Carlo analysis","volume":"71","author":"A Minelli","year":"2011","journal-title":"SIAM Journal on Applied Mathematics"},{"key":"pcbi.1011247.ref024","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5291823","article-title":"Dendritic immunotherapy improvement for an optimal control murine model","volume":"2017","author":"J Rangel-Reyes","year":"2017","journal-title":"Computational and mathematical methods in medicine"},{"key":"pcbi.1011247.ref025","doi-asserted-by":"crossref","first-page":"110067","DOI":"10.1016\/j.jtbi.2019.110067","article-title":"Optimisation of anti-cancer peptide vaccines to preferentially elicit high-avidity T cells","volume":"486","author":"A Kumbhari","year":"2020","journal-title":"Journal of Theoretical Biology"},{"issue":"4","key":"pcbi.1011247.ref026","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jtbi.2007.04.003","article-title":"Cancer immunotherapy, mathematical modeling and optimal control","volume":"247","author":"F Castiglione","year":"2007","journal-title":"Journal of theoretical Biology"},{"key":"pcbi.1011247.ref027","doi-asserted-by":"crossref","first-page":"635524","DOI":"10.3389\/fdgth.2021.635524","article-title":"Personalised, rational, efficacy-driven cancer drug dosing via an artificial intelligence SystEm (PRECISE): a protocol for the PRECISE CURATE. AI pilot clinical trial","volume":"3","author":"BKJ Tan","year":"2021","journal-title":"Frontiers in digital health"},{"issue":"15","key":"pcbi.1011247.ref028","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"R Simon","year":"1997","journal-title":"Journal of the National Cancer Institute"},{"key":"pcbi.1011247.ref029","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1200\/EDBK_319783","article-title":"Moving beyond 3+ 3: the future of clinical trial design","volume":"41","author":"R Kurzrock","year":"2021","journal-title":"American Society of Clinical Oncology Educational Book"},{"issue":"18","key":"pcbi.1011247.ref030","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/1078-0432.CCR-13-2671","article-title":"Is the \u201c3+ 3\u201d dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design","volume":"20","author":"OE Rahma","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"pcbi.1011247.ref031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-pharmtox-010617-052446","article-title":"Precision medicine is not just genomics: the right dose for every patient","volume":"58","author":"RW Peck","year":"2018","journal-title":"Annual review of pharmacology and toxicology"},{"key":"pcbi.1011247.ref032","article-title":"US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer","author":"SS Shord","journal-title":"CPT: pharmacometrics & systems pharmacology;"},{"issue":"9","key":"pcbi.1011247.ref033","doi-asserted-by":"crossref","first-page":"e1009318","DOI":"10.1371\/journal.pcbi.1009318","article-title":"Mathematical model of a personalized neoantigen cancer vaccine and the human immune system","volume":"17","author":"M Rodriguez Messan","year":"2021","journal-title":"PLoS computational biology"},{"issue":"7662","key":"pcbi.1011247.ref034","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"PA Ott","year":"2017","journal-title":"Nature"},{"key":"pcbi.1011247.ref035","doi-asserted-by":"crossref","DOI":"10.1201\/9781420011418","volume-title":"Optimal control applied to biological models","author":"S Lenhart","year":"2007"},{"issue":"2","key":"pcbi.1011247.ref036","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11538-005-9014-3","article-title":"Optimal control in a model of dendritic cell transfection cancer immunotherapy","volume":"68","author":"F Castiglione","year":"2006","journal-title":"Bulletin of Mathematical Biology"},{"key":"pcbi.1011247.ref037","doi-asserted-by":"crossref","first-page":"111647","DOI":"10.1016\/j.jtbi.2023.111647","article-title":"Optimal control applied to Zika virus epidemics in Colombia and Puerto Rico","volume":"575","author":"W Valega-Mackenzie","year":"2023","journal-title":"Journal of Theoretical Biology"},{"issue":"10","key":"pcbi.1011247.ref038","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/dom.12304","article-title":"Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial","volume":"16","author":"T Heise","year":"2014","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"1","key":"pcbi.1011247.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(02)00338-2","article-title":"Autoreactive CD8 T cells in organ-specific autoimmunity: emerging targets for therapeutic intervention","volume":"17","author":"RS Liblau","year":"2002","journal-title":"Immunity"},{"issue":"11","key":"pcbi.1011247.ref040","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1365-2222.2006.02606.x","article-title":"Regulation of the T cell response","volume":"36","author":"S Romagnani","year":"2006","journal-title":"Clinical & Experimental Allergy"},{"issue":"1","key":"pcbi.1011247.ref041","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10589-011-9454-7","article-title":"Convergence of the forward-backward sweep method in optimal control","volume":"53","author":"M McAsey","year":"2012","journal-title":"Computational Optimization and Applications"},{"key":"pcbi.1011247.ref042","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1026578104213","article-title":"Deterministic global optimization in nonlinear optimal control problems","volume":"17","author":"WR Esposito","year":"2000","journal-title":"Journal of global optimization"},{"key":"pcbi.1011247.ref043","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10898-005-7074-4","article-title":"Global optimization with nonlinear ordinary differential equations","volume":"34","author":"AB Singer","year":"2006","journal-title":"Journal of Global Optimization"},{"key":"pcbi.1011247.ref044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v060.i06","article-title":"Continuous global optimization in R","volume":"60","author":"KM Mullen","year":"2014","journal-title":"Journal of Statistical Software"},{"key":"pcbi.1011247.ref045","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.ejco.2023.100067","article-title":"A framework using nested partitions algorithm for convergence analysis of population distribution-based methods","volume":"11","author":"MH Chauhdry","year":"2023","journal-title":"EURO Journal on Computational Optimization"},{"issue":"3","key":"pcbi.1011247.ref046","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4161\/hv.27332","article-title":"Recent progress in adjuvant discovery for peptide-based subunit vaccines","volume":"10","author":"F Azmi","year":"2014","journal-title":"Human vaccines & immunotherapeutics"},{"key":"pcbi.1011247.ref047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0327-9","article-title":"Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model","volume":"6","author":"Y Kosinsky","year":"2018","journal-title":"Journal for immunotherapy of cancer"},{"key":"pcbi.1011247.ref048","first-page":"1","article-title":"Combination immunotherapy: a road map","volume":"5","author":"PA Ott","year":"2017","journal-title":"Journal for immunotherapy of cancer"},{"key":"pcbi.1011247.ref049","doi-asserted-by":"crossref","first-page":"663264","DOI":"10.3389\/fonc.2021.663264","article-title":"Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment","volume":"11","author":"JY Liao","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"4","key":"pcbi.1011247.ref050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"E Blass","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"12","key":"pcbi.1011247.ref051","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s43588-022-00377-z","article-title":"Mathematical modeling of cancer immunotherapy for personalized clinical translation","volume":"2","author":"JD Butner","year":"2022","journal-title":"Nature Computational Science"},{"issue":"3","key":"pcbi.1011247.ref052","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Z Hu","year":"2021","journal-title":"Nature medicine"},{"key":"pcbi.1011247.ref053","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2022.1007784","article-title":"Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation","volume":"4","author":"EA Stahlberg","year":"2022","journal-title":"Frontiers in Digital Health"},{"key":"pcbi.1011247.ref054","article-title":"Systems-based Digital Twins to Help Characterize Clinical Dose-Response and Propose Predictive Biomarkers in a Phase I Study of Bispecific Antibody, Mosunetuzumab, in NHL","author":"ME Susilo","year":"2023","journal-title":"Clinical and Translational Science"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1011247","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T13:48:23Z","timestamp":1710337703000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1011247"}},"subtitle":[],"editor":[{"given":"Anders","family":"Wallqvist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1011247","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.06.09.544293","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}